RGA Stock Analysis: Reinsurance of America | NYSE
Insurance - Reinsurance | NYSE, USA | Market Cap: 14.478m USD | 12M Return: 17.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 76.9M
EPS Trend: 77.6%
Qual. Beats: 2
Rev. Trend: 92.1%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Reinsurance Group of America (RGA) is a large-cap U.S. reinsurer founded in 1973 and headquartered in Chesterfield, Missouri. The company provides life and health reinsurance along with asset-intensive reinsurance products to clients across the U.S., Latin America, Canada, Europe, the Middle East, Africa, Asia, and Australia. Its portfolio includes individual and group life and health, disability, long-term care, and critical illness reinsurance, as well as financial solutions covering longevity risk, pension risk transfer, stable value products, and capital solutions such as funding agreement backed notes.
RGA also reinsures mortality, morbidity, lapse, and investment-related risks, and participates in payout annuity coinsurance and underwritten annuity programs. Reinsurance functions as a risk-transfer layer for primary insurers, allowing cedents to offload portions of underwriting and investment exposure in exchange for premium cessions, which is a structural feature of the sector that distinguishes reinsurers from direct insurers.
- Rising rates lift reinvestment yields on asset-intensive portfolio
- Pension risk transfer and longevity reinsurance volumes accelerate
- USD strength pressures reported earnings from international segments
| Net Income: 1.23b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.58 > 1.0 |
| NWC/Revenue: 24.68% < 20% (prev 18.52%; Δ 6.16% < -1%) |
| CFO/TA 0.03 > 3% & CFO 5.54b > Net Income 1.23b |
| Net Debt (1.11b) to EBITDA (1.66b): 0.67 < 3 |
| Current Ratio: 2.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (66.7m) vs 12m ago -0.19% < -2% |
| Gross Margin: 20.33% > 18% (prev 12.48%; Δ 7.85% > 0.5%) |
| Asset Turnover: 16.83% > 50% (prev 16.35%; Δ 0.47% > 0%) |
| Interest Coverage Ratio: 4.19 > 6 (EBIT TTM 1.61b / Interest Expense TTM 385.0m) |
| A: 0.04 (Total Current Assets 9.25b - Total Current Liabilities 3.18b) / Total Assets 164b |
| B: 0.06 (Retained Earnings 10.4b / Total Assets 164b) |
| C: 0.01 (EBIT TTM 1.61b / Avg Total Assets 146b) |
| D: 0.09 (Book Value of Equity 13.3b / Total Liabilities 151b) |
| Altman-Z'' = 0.62 = B |
| DSRI: 0.97 (Receivables 4.26b/3.75b, Revenue 24.6b/21.0b) |
| GMI: 0.61 (GM 12.48% / 20.33%) |
| AQI: 1.01 (AQ_t 0.94 / AQ_t-1 0.93) |
| SGI: 1.17 (Revenue 24.6b / 21.0b) |
| TATA: -0.03 (NI 1.23b - CFO 5.54b) / TA 164b) |
| Beneish M = -3.27 (Cap -4..+1) = AA |
As of July 09, 2026, the stock is trading at USD 227.62 with a total of 262,514 shares traded. Over the past week, the price has changed by +7.04%, over one month by +13.13%, over three months by +8.19% and over the past year by +17.26%.
Current recommended Stop Loss: 219.20 (which is 3.7% or 1.7 ATR below the current price).
Reinsurance of America has received a consensus analysts rating of 3.90. Therefore, it is recommended to buy RGA.
- StrongBuy: 3
- Buy: 3
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 252.2 | 10.8% |
P/E Trailing = 12.0174
P/E Forward = 8.2781
P/S = 0.5807
P/B = 1.0627
P/EG = 1.1437
Revenue TTM = 24.6b USD
EBIT TTM = 1.61b USD
EBITDA TTM = 1.66b USD
Long Term Debt = 6.11b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 6.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.11b USD (calculated: Debt 6.11b - CCE 4.99b)
Enterprise Value = 15.6b USD (14.5b + Debt 6.11b - CCE 4.99b)
Interest Coverage Ratio = 4.19 (Ebit TTM 1.61b / Interest Expense TTM 385.0m)
EV/FCF = 2.82x (Enterprise Value 15.6b / FCF TTM 5.54b)
FCF Yield = 35.50% (FCF TTM 5.54b / Enterprise Value 15.6b)
FCF Margin = 22.51% (FCF TTM 5.54b / Revenue TTM 24.6b)
Net Margin = 4.98% (Net Income TTM 1.23b / Revenue TTM 24.6b)
Gross Margin = 20.33% ((Revenue TTM 24.6b - Cost of Revenue TTM 19.6b) / Revenue TTM)
Gross Margin QoQ = 28.61% (prev 26.26%)
Tobins Q-Ratio = 0.10 (Enterprise Value 15.6b / Total Assets 164b)
Interest Expense / Debt = 6.31% (Interest Expense 385.0m / Debt 6.11b)
Taxrate = 23.57% (380.0m / 1.61b)
NOPAT = 1.23b (EBIT 1.61b * (1 - 23.57%))
Current Ratio = 2.91 (Total Current Assets 9.25b / Total Current Liabilities 3.18b)
Debt / Equity = 0.46 (Debt 6.11b / totalStockholderEquity, last quarter 13.3b)
Debt / EBITDA = 0.67 (Net Debt 1.11b / EBITDA 1.66b)
Debt / FCF = 0.20 (Net Debt 1.11b / FCF TTM 5.54b)
Total Stockholder Equity = 12.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.84% (Net Income 1.23b / Total Assets 164b)
RoE = 9.47% (Net Income TTM 1.23b / Total Stockholder Equity 12.9b)
RoCE = 8.46% (EBIT 1.61b / Capital Employed (Equity 12.9b + L.T.Debt 6.11b))
RoIC = 0.77% (NOPAT 1.23b / Invested Capital 160b)
WACC = 7.26% (E(14.5b)/V(20.6b) * Re(8.29%) + D(6.11b)/V(20.6b) * Rd(6.31%) * (1-Tc(0.24)))
Discount Rate = 8.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 7.16 | Cagr: 0.01%
[DCF] Terminal Value 76.59% ; FCFF base≈5.35b ; Y1≈5.78b ; Y5≈7.11b
[DCF] Fair Price = 1.64k (EV 109b - Net Debt 1.11b = Equity 108b / Shares 65.5m; r=8.35% [WACC [floored]]; 5y FCF grow 9.32% → 2.50% )
EPS Correlation: 77.60 | EPS CAGR: 8.37% | SUE: 0.90 | # QB: 2
Revenue Correlation: 92.05 | Revenue CAGR: 12.36% | SUE: 0.04 | # QB: 0
EPS current Quarter (2026-06-30): EPS=6.53 | Chg30d=+0.54% | Revisions=+10% | Analysts=9
EPS next Quarter (2026-09-30): EPS=6.87 | Chg30d=+0.76% | Revisions=+30% | Analysts=9
EPS current Year (2026-12-31): EPS=27.07 | Chg30d=+3.81% | Revisions=+42% | GrowthEPS=+19.1% | GrowthRev=+13.5%
EPS next Year (2027-12-31): EPS=29.02 | Chg30d=+0.52% | Revisions=+36% | GrowthEPS=+7.2% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: +38% (up=22, down=9)